Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01034267 · ClinicalTrials.gov registry record · Phase 3
Safety Study of F2695 SR in Major Depressive Disorder
A Phase 3 study of Major Depressive Disorder, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 828
- Enrollment target
- 20
- Study locations
NCT01034267: Completed Phase 3 study of Major Depressive Disorder, sponsored by Forest Laboratories.
NCT01034267 is a Phase 3 study of Major Depressive Disorder that has completed, run by Forest Laboratories. The registered enrollment target is 828 participants, above the 374-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (121% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01034267, a Phase 3 study of Major Depressive Disorder, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 828 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the long- term safety of F2695-SR in the treatment of adults with major depressive disorder.
Conditions Studied
Interventions
- DRUG F2695 SR
Study Locations (20)
Florida
- Forest Investigative Site 57 - Boca Raton
- Forest Investigative Site 60 - Boca Raton
- Forest Investigative Site 18 - Coral Springs
- Forest Investigative Site 34 - Fort Myers
- Forest Investigative Site 64 - Gainesville
- Forest Investigative Site 45 - Hallandale
- Forest Investigative Site 17 - Jacksonville
- Forest Investigative Site 53 - Ocala
California
- Forest Investigative Site 31 - Beverly Hills
- Forest Investigative Site 3 - Costa Mesa
- Forest Investigative Site 12 - Encino
- Forest Investigative Site 6 - Escondido
- Forest Investigative Site 22 - Oceanside
- Forest Investigative Site 38 - Sherman Oaks
Colorado
- Forest Investigative Site 36 - Denver
- Forest Investigative Site 28 - Denver
- Forest Investigative Site 65 - Highlands Ranch
Alabama
- Forest Investigative Site 55 - Dothan
Arizona
- Forest Investigative Site 29 - Scottsdale
Connecticut
- Forest Investigative Site 30 - Cromwell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 828 participants |
| Start Date | 2009-12 |
| Phase | Phase 3 |
What the finished NCT01034267 record still lists
NCT01034267 is an interventional study that assigns participants to a tested intervention. The registered 828 participants enrollment target is mid-sized for trials with a published cap, above the 374-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (121% higher).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which F2695 SR is the first listed.
NCT01034267 names 20 study sites across 6 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT01034267 about?
NCT01034267 is a clinical study titled "Safety Study of F2695 SR in Major Depressive Disorder". The purpose of this study is to evaluate the long- term safety of F2695-SR in the treatment of adults with major depressive disorder.
What is the current status of trial NCT01034267?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 828 participants. The study started on 2009-12.
What conditions does trial NCT01034267 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT01034267?
The interventions under investigation include: F2695 SR (DRUG).
Who is sponsoring clinical trial NCT01034267?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01034267 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01034267's enrollment target sits among peer trials
828 12th of 282 higher than 271 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
Study to Assess the Safety and Effectiveness of NMRA-335140-501
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
RECRUITING · Phase 3
-
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
RECRUITING · Phase 3
-
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05124808 · 828 participants · NA
Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
- NCT03547973 · 827 participants · Phase 2
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
- NCT05067283 · 830 participants · Phase 1
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- NCT06592924 · 830 participants · Phase 3
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia